Ex Vivo Capabilities
Ex Vivo Drug Sensitivity Platforms to Compliment In Vivo Studies
Champions Oncology has developed a platform for drug testing in ex vivo 2-D and 3-D cultures derived from our patient derived xenografts, and syngeneic and human cell lines. Utilizing Cypre Symphony™ and Versagel™ technologies in 24- or 96-well formats, our offering enables the rapid development of high throughput tumor cell cultures for both traditional and immuno-oncology applications than can enhance early discovery research and de-risk in vivo studies.
The ex vivo platform is offered in several packages:
- Lead Selection/Optimization: Testing of multiple compounds in discovery phase across a small cohort of cell cultures derived from PDX models in order to assess drug activity and development potential
- Target Validation/Early Discovery: Testing of multiple models with defined target expression/genomic profile in a high-throughput setting in order to better identify and validate drug targets
- Ex Vivo/In Vivo Package: De-risking of in vivo studies by testing of multiple models in ex vivo setting with commitment to run a number of models in vivo as a result of drug activity
- Indication Screen: Selection of a large number of models from one or more indications to assess drug activity in defined patient cohorts.
Immuno-Oncology Ex Vivo Platforms
Utilize Champions Oncology’s ex vivo platforms to address mechanisms of action for immuno-oncology agents. Using multiplex 2-D cytokine assays with flow cytometry readouts, immune cell cytokine intracellular and extracellular staining upon activation can be assessed.
Register for our latest webinar, Ex Vivo/In Vivo Platforms for Translational Oncology Research.
View a video about Ex Vivo Capabilities at Champions Oncology.